Other formats:
BibTeX
LaTeX
RIS
@misc{2365870,
author = {Žáčková, Daniela},
booktitle = {Brno-Vienna Collaboration meeting 2023, General Hospital of Vienna, Vienna, Rakousko, 2. 6. 2023},
keywords = {chronic myeloid leukemia; HALF; CLINICAL TRIAL; TKI},
language = {eng},
title = {CML stopping trial HALF: Concept and Initial Data},
url = {https://czecrin.cz/projekty/kh-half/},
year = {2023}
}
TY - SLIDE
ID - 2365870
AU - Žáčková, Daniela
PY - 2023
TI - CML stopping trial HALF: Concept and Initial Data
KW - chronic myeloid leukemia
KW - HALF
KW - CLINICAL TRIAL
KW - TKI
UR - https://czecrin.cz/projekty/kh-half/
N2 - A prospective phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitor withdrawal after prior two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission The HALF clinical trial is designed as a prospective, multicenter, nonrandomized, open-label phase II study to assess the efficacy and safety of tyrosine kinase inhibitor withdrawal after a prior two-step dose reduction in patients with chronic myeloid leukemia in deep remission. The clinical evaluation of HALF could contribute to the formulation of a new disease management strategy for patients achieving sustained remission with the potential for wider benefits not only for the patients themselves, but also for the healthcare system.
ER -
ŽÁČKOVÁ, Daniela. CML stopping trial HALF: Concept and Initial Data. In \textit{Brno-Vienna Collaboration meeting 2023, General Hospital of Vienna, Vienna, Rakousko, 2. 6. 2023}. 2023.
|
